Podcast Episodes
Back to Search
Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
Season 7 Episode 389
Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowd…
1 month, 3 weeks ago
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
Season 7 Episode 388
The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of rever…
2 months ago
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Season 7 Episode 387
Note: This episode was briefly published with an incorrect audio file, which has since been corrected.
FDA is prepared to approve psychedelic therapie…
2 months, 1 week ago
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Season 7 Episode 386
A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III mis…
2 months, 1 week ago
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Season 7 Episode 385
Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCent…
2 months, 2 weeks ago
Ep. 384 - Back to School Special: The global FIH trials race
China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and …
2 months, 3 weeks ago
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
Season 7 Episode 383
A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury…
2 months, 4 weeks ago
Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
Season 7 Episode 382
A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, Bi…
3 months ago
Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
Season 7 Episode 381
Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human tr…
3 months, 1 week ago
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
Season 7 Episode 380
Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week …
3 months, 2 weeks ago